Primary Sjogren's Syndrome: Current and Prospective Therapies

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 5, 2008, Pages 273-292

  Thanou Stavraki, Aikaterini ^a,b   James, Judith A ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

anti TNF ; biologics; dry eye; dry mouth; lymphoma; primary Sjogren's syndrome; rituximab; sicca syndrome; treatment

Indexed keywords

12 SULFODEHYDROABIETIC ACID; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN A; DIQUAFOSOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; ESTRATEST; EYE DROPS; GEFARNATE; IMMUNOSUPPRESSIVE AGENT; MUSCARINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PIMECROLIMUS; REBAMIPIDE; RECOMBINANT INTERLEUKIN 10; RITUXIMAB; TACROLIMUS; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; B CELL LYMPHOMA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRY EYE; EYE DISCHARGE; GLOMERULONEPHRITIS; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; LACRIMAL GLAND DISEASE; LACRIMATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MEDLINE; MENOPAUSAL SYNDROME; NEUROLOGIC DISEASE; PATIENT MONITORING; POLYARTHRITIS; PRIORITY JOURNAL; SALIVATION; SJOEGREN SYNDROME; TOPICAL TREATMENT; TREATMENT OUTCOME; VASCULITIS; VIRAL GENE DELIVERY SYSTEM; XEROSTOMIA;

ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; SJOGREN'S SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40749148843     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.06.002     Document Type: Article

References (251)

1. Ramos-Casals M., Brito-Zeron P., and Font J. The overlap of Sjogren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 36 (2007) 246-255
2. Bowman S.J., Ibrahim G.H., Holmes G., Hamburger J., and Ainsworth J.R. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 33 (2004) 39-43
3. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002) 554-558
4. Ramos-Casals M., Tzioufas A.G., and Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 64 (2005) 347-354
5. Garcia-Carrasco M., Ramos-Casals M., Rosas J., Pallares L., Calvo-Alen J., Cervera R., et al. Primary Sjogren syndrome. Cinical and immunologic disease patterns in a cohort of 400 patients. Medicine 81 (2002) 270-280
6. Delalande S., de Seze J., Fauchais A.L., Hachulla E., Stojkovic T., Ferriby D., et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 83 (2004) 280-291
7. Ramos-Casals M., Anaya J.M., Garcia-Carrasco M., Rosas J., Bove A., Claver G., et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 83 (2004) 96-106
8. Ramos-Casals M., Font J., Garcia-Carrasco M., Brito M.P., Rosas J., Calvo-Alen J., et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 81 (2002) 281-292
9. Voulgarelis M., Dafni U.G., Isenberg D.A., and Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42 (1999) 1765-1772
10. Fox R.I. Sjogren's syndrome. Lancet 366 (2005) 321-331
11. Ioannidis J.P., Vassiliou V.A., and Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46 (2002) 741-747
12. Skopouli F.N., Dafni U., Ioannidis J.P., and Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 29 (2000) 296-304
13. Kassan S.S., and Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164 (2004) 1275-1284
14. Foulks G.N. The evolving treatment of dry eye. Ophthalmol Clin North Am 16 (2003) 29-35
15. Wolkoff P., Nojgaard J.K., Franck C., and Skov P. The modern office environment desiccates the eyes?. Indoor Air 16 (2006) 258-265
16. Shah C., Raj C.V., and Foulks G.N. The evolution in therapeutic contact lenses. Ophthalmol Clin North Am 16 (2003) 95-101
17. Korb D.R., Scaffidi R.C., Greiner J.V., Kenyon K.R., Herman J.P., Blackie C.A., et al. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. Optom Vis Sci 82 (2005) 594-601
18. Aragona P., Di Stefano G., Ferreri F., Spinella R., and Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients. Br J Ophthalmol 86 (2002) 879-884
19. Cohen E.J. Punctal occlusion. Arch Ophthalmol 117 (1999) 389-390
20. Demartelaere S.L., Blaydon S.M., Tovilla-Canales J.L., and Shore J.W. A permanent and reversible procedure to block tear drainage for the treatment of dry eye. Ophthal Plast Reconstr Surg 22 (2006) 352-355
21. Miyata K., Otani S., Miyai T., Nejima R., and Amano S. Atelocollagen punctal occlusion in dry eye patients. Cornea 25 (2006) 47-50
22. Yen M.T., Pflugfelder S.C., and Feuer W.J. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol 131 (2001) 314-323
23. Noble B.A., Loh R.S., MacLennan S., Pesudovs K., Reynolds A., Bridges L.R., et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 88 (2004) 647-652
24. Kojima T., Ishida R., Dogru M., Goto E., Matsumoto Y., Kaido M., et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 139 (2005) 242-246
25. Geerling G., Maclennan S., and Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 88 (2004) 1467-1474
26. Liu L., Hartwig D., Harloff S., Herminghaus P., Wedel T., Kasper K., et al. Corneal epitheliotrophic capacity of three different blood-derived preperations. Invest Ophthalmol Vis Sci 47 (2006) 2438-2444
27. Fox R.I., Konttinen Y., and Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol 101 (2001) 249-263
28. Papas A.S., Fernandez M.M., Castano R.A., Gallagher S.C., Trivedi M., and Shrotriya R.C. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogrens syndrome. Adv Exp Med Biol 438 (1998) 973-978
29. Vivino F.B., Al-Hashimi I., Khan Z., LeVeque F.G., Salisbury III P.L., Tran-Johnson T.K., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms inpatients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159 (1999) 174-181
30. Tsifetaki N., Kitsos G., Paschides C.A., Alamanos Y., Eftaxias V., Voulgari P.V., et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 62 (2003) 1204-1207
31. Petrone D., Condemi J.J., Fife R., Gluck O., Cohen S., and Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46 (2002) 748-754
32. Ono M., Takamura E., Shinozaki K., Tsumura T., Hamano T., Yagi Y., et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 138 1 (2004) 6-17
33. Gipson I.K., and Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol 231 (2003) 1-49
34. Murakami T., Fujihara T., Horibe Y., and Nakamura M. Diquafosol elicits increases in net Cl[minud] transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res 36 (2004) 89-93
35. Tauber J., Davitt W.F., Bokosky J.E., Nichols K.K., Yerxa B.R., Schaberg A.E., et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23 (2004) 784-792
36. Foulks G., Sall K., Greenberg M., Tauber J., Donshik P., Berdy G., et al. Phase II dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with dry eye. Invest Ophthalmol Vis Sci 42 (2001) S713 (3839)
37. Jumblatt J.E., Cunningham L.T., Li Y., and Jumblatt M.M. Characterization of human ocular mucin secretion mediated by 15(S)-HETE. Cornea 21 (2002) 818-824
38. Inatomi T., Spurr-Michaud S., Tisdale A.S., and Gipson I.K. Human corneal and conjunctival epithelia express MUC1 mucin. Invest Ophthalmol Vis Sci 36 (1995) 1818-1827
39. Jackson II R.S., Van Dyken S.J., McCartney M.D., and Ubels J.L. The eicosanoid, 15-(S)-HETE, stimulates secretion of mucin-like glycoprotein by the corneal epithelium. Cornea 20 (2001) 516-521
40. Gamache D.A., Wei Z.Y., Weimer L.K., Miller S.T., Spellman J.M., and Yanni J.M. Corneal protection by the ocular mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced corneal defect. J Ocul Pharmacol Ther 18 (2002) 349-361
41. Urashima H., Okamoto T., Takeji Y., Shinohara H., and Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 23 (2004) 613-619
42. Donshik P.C., Foulks G., Monica M., Zhang P., Tano A., Nakatsu S., et al. Multicenter, Randomized, Double-Masked, Dose-Response, Placebo-Controlled, Parallel-Group Study of the safety and efficacy of rebamipide (OPC-12759) sterile ophthalmic suspension in the treatment of dry eye. Invest Ophthalmol Vis Sci 46 (2005) (Abstract)
43. Nakamura M., Endo K., Nakata K., and Hamano T. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res 65 (1997) 569-574
44. Toshida H., Nakata K., Hamano T., Nakamura M., Nguyen D., and Beuerman R.W. Effect of gefarnate on the ocular surface in squirrel monkeys. Cornea 21 (2002) 292-299
45. Laibovitz R.A., Solch S., Andriano K., O'Connell M., and Silverman M.H. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 12 (1993) 315-323
46. Gunduz K., and Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh) 72 (1994) 438-442
47. Sall K., Stevenson O.D., Mundorf T.K., and Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease CsA Phase III Study Group. Ophthalmology 107 (2000) 631
48. Kunert K.S., Tisdale A.S., Stern M.E., Smith J.A., and Gipson I.K. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 118 (2000) 1489-1496
49. Kunert K.S., Tisdale A.S., and Gipson I.K. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 120 (2002) 330-337
50. Stevenson D., Tauber J., and Reis B.L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. Ophthalmology 107 (2000) 967-974
51. Power W.J., Mullaney P., Farrell M., and Collum L.M. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren's syndrome. Cornea 12 (1993) 507-511
52. Kujawa A., and Rozycki R. A 0,05% cyclosporine treatment of the advanced dry eye syndrome. Klin Oczna 107 (2005) 280-286
53. Stonecipher K., Perry H.D., Gross R.H., and Kerney D.L. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin 21 (2005) 1057-1063
54. Barber L.D., Pflugfelder S.C., Tauber J., and Foulks G.N. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 112 (2005) 1790-1794
55. Tang-Liu D.D., and Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet 44 (2005) 247-261
56. Brignole F., Pisella P.J., De Saint Jean M., Goldschild M., Goguel A., and Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 42 (2001) 90-95
57. Strong B., Farley W., Stern M.E., and Pflugfelder S.C. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 24 (2005) 80-85
58. Drosos A.A., Skopouli F.N., Costopoulos J.S., Papadimitriou C.S., and Moutsopoulos H.M. Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis 45 (1986) 732-735
59. Dalavanga Y.A., Detrick B., Hooks J.J., Drosos A.A., and Moutsopoulos H.M. Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjogren's syndrome. Ann Rheum Dis 46 (1987) 89-92
60. Berdoulay A., English R.V., and Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 8 (2005) 225-232
61. Rikkers S.M., Holland G.N., Drayton G.E., Michel F.K., Torres M.F., and Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 135 (2003) 297-302
62. Nell B., Walde I., Billich A., Vit P., and Meingassner J.G. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol 8 (2005) 39-46
63. Ousler G.W., Haque R., Weichselberger A., Yannoulis N.C., and Abelson M.B. Comparison of pimecrolimus 1%, 0.3% and 0.1% with vehicle for the treatment of dry eye in the controlled adverse environment (CAE) model. Invest Ophthalmol Vis Sci 46 (2005) (Abstract)
64. Marsh P., and Pflugfelder S.C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106 (1999) 811-816
65. Avunduk A.M., Avunduk M.C., Varnell E.D., and Kaufman H.E. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 136 (2003) 593-602
66. Bodor N., and Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 20 (2000) 58-101
67. Pflugfelder S.C., Maskin S.L., Anderson B., Chodosh J., Holland E.J., De Paiva C.S., et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 138 (2004) 444-457
68. Leibowitz H.M., Bartlett J.D., Rich R., McQuirter H., Stewart R., and Assil K. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol 114 (1996) 933-937
69. Aragona P., Stilo A., Ferreri F., and Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren's syndrome patients. Eye 19 (2005) 535-539
70. Sullivan D.A., and Edwards J.A. Androgen stimulation of lacrimal gland function in mouse models of Sjogren's syndrome. J Steroid Biochem Mol Biol 60 (1997) 237-245
71. Bizzarro A., Valentini G., Di Martino G., DaPonte A., De Bellis A., and Iacono G. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. J Clin Endocrinol Metab 64 (1987) 32-36
72. Worda C., Nepp J., Huber J.C., and Sator M.O. Treatment of keratoconjunctivitis sicca with topical androgen. Maturitas 37 (2001) 209-212
73. Scott G., Yiu S.C., Wasilewski D., Song J., and Smith R.E. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am J Ophthalmol 139 (2005) 1109-1110
74. Sullivan D.A., Wickham L.A., Rocha E.M., Kelleher R.S., da Silveira L.A., and Toda I. Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. Adv Exp Med Biol 438 (1998) 11-42
75. Sullivan D.A., Sullivan B.D., Evans J.E., Schirra F., Yamagami H., Liu M., et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann NY Acad Sci 966 (2002) 211-222
76. Azzarolo A.M., Wood R.L., Mircheff A.K., Richters A., Olsen E., Berkowitz M., et al. Androgen influence on lacrimal gland apoptosis, necrosis, and lymphocytic infiltration. Invest Ophthalmol Vis Sci 40 (1999) 592-602
77. Rocha E.M., Wickham L.A., da Silveira L.A., Krenzer K.L., Yu F.S., Toda I., et al. Identification of androgen receptor protein and 5-alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 84 (2000) 76-84
78. Worda C., Nepp J., Huber J.C., and Sator M.O. Treatment of keratoconjunctivitis sicca with topical androgen. Maturitas 37 (2001) 209-212
79. Connor C.G. Retrospective analysis of dry eye patients using 3% transdermal testosterone cream. Invest Ophthalmol Vis Sci 45 (2004) (Abstract)
80. Connor C.G. No increase in IOP observed in patients using transdermal testosterone for three years. Invest Ophthalmol Vis Sci 47 (2006) (Abstract)
81. Silvestre-Donat F.J., Miralles-Jorda L., and Martinez-Mihi V. Protocol for the clinical management of dry mouth. Med Oral 9 (2004) 273-279
82. Porter S.R., Scully C., and Hegarty A.M. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 (2004) 28-46
83. Fox P.C., Cummins M.J., and Cummins J.M. A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sjogren's syndrome. J Altern Complement Med 8 (2002) 651-659
84. Wynn R.L., and Meiller T.F. Artificial saliva products and drugs to treat xerostomia. Gen Dent 48 (2000) 630-636
85. Urquhart D., and Fowler C.E. Review of the use of polymers in saliva substitutes for symptomatic relief of xerostomia. J Clin Dent 17 (2006) 29-33
86. Al-Hashimi I., and Taylor S.E. A new medication for treatment of dry mouth in Sjogren's syndrome. Tex Dent J 118 (2001) 262-266
87. Frost P.M., Gardner R.M., Price A.R., and Sinclair G.F. A preliminary assessment of intra-oral lubricating systems for dry mouth patients. Gerodontology 14 (1997) 54-58
88. Robinson P.G., Pankhurst C.L., and Garrett E.J. Randomized-controlled trial: effect of a reservoir biteguard on quality of life in xerostomia. J Oral Pathol Med 34 (2005) 193-197
89. Fox P.C., Atkinson J.C., Macynski A.A., Wolff A., Kung D.S., Valdez I.H., et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151 (1991) 1149-1152
90. Fife R.S., Chase W.F., Dore R.K., Wiesenhutter C.W., Lockhart P.B., Tindall E., et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med 162 (2002) 1293-1300
91. Rosas J., Ramos-Casals M., Ena J., Garcia-Carrasco M., Verdu J., Cervera R., et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren's syndrome. Correlation with clinical, immunological and histological features. Rheumatology (Oxford) 41 (2002) 670-675
92. Wu C.H., Hsieh S.C., Lee K.L., Li K.J., Lu M.C., and Yu C.L. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjogren's Syndrome in Taiwan. A double-blind, placebo-controlled trial. J Formos Med Assoc 10 (2006) 796-803
93. Yamada H., Nakagawa Y., Wakamatsu E., Sumida T., Yamachika S., Nomura Y., et al. Efficacy prediction of cevimeline in patients with Sjogren's syndrome. Clin Rheumatol (2007) [Epub ahead of print]
94. Shiozawa S., Morimoto I., Tanaka Y., and Shiozawa K. A preliminary study on the interferon-alpha treatment for xerostomia of Sjogren's syndrome. Br J Rheumatol 32 (1993) 52-54
95. Ferraccioli G.F., Salaffi F., De Vita S., Casatta L., Avellini C., Carotti M., et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 14 (1996) 367-371
96. Shiozawa S., Tanaka Y., and Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 18 (1998) 255-262
97. Ship J.A., Fox P.C., Michalek J.E., Cummins M.J., and Richards A.B. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. J Interferon ytokine Res 19 (1999) 943-951
98. Khurshudian A.V. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 38-44
99. Cummins M.J., Papas A., Kammer G.M., and Fox P.C. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 49 (2003) 585-593
100. Smith J.K., Siddiqui A.A., Modica L.A., Dykes R., Simmons C., Schmidt J., et al. Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res 19 (1999) 929-935
101. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52 (2005) 1185-1195
102. Nordmark G., Alm G.V., and Ronnblom L. Mechanisms of Disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2 (2006) 262-269
103. Fox P.C., Datiles M., Atkinson J.C., Macynski A.A., Scott J., Fletcher D., et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 11 (1993) 149-156
104. Miyawaki S., Nishiyama S., and Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome. Intern Med 38 (1999) 938-943
105. Pijpe J., Kalk W.W., Bootsma H., Spijkervet F.K., Kallenberg C.G., and Vissink A. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis 66 (2007) 107-112
106. Izumi M., Eguchi K., Nakamura H., Takagi Y., Kawabe Y., and Nakamura T. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome. Ann Rheum Dis 57 (1998) 464-469
107. Kok M.R., Baum B.J., Tak P.P., and Pillemer S.R. Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjogren's syndrome. Ann Rheum Dis 62 (2003) 1038-1046
108. Kok M.R., Yamano S., Lodde B.M., Wang J., Couwenhoven R.I., Yakar S., et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum Gene Ther 14 (2003) 1605-1618
109. Lodde B.M., Mineshiba F., Wang J., Cotrim A.P., Afione S., Tak P.P., et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 65 (2006) 195-200
110. Lodde B.M., Baum B.J., Tak P., and Illei G. Experience with experimental biological treatment and local gene therapy of Sjogren's syndrome: implications for exocrine pathogenesis and treatment. Ann Rheum Dis 65 (2006) 1406-1413
111. Trousdale M.D., Zhu Z., Stevenson D., Schechter J.E., Ritter T., and Mircheff A.K. Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J Autoimmune Dis 2 (2005) 6
112. Azuma M., Aota K., Tamatani T., Motegi K., Yamashita T., Ashida Y., et al. Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis Rheum 46 (2002) 1585-1594
113. Azuma M., Ashida Y., Tamatani T., Motegi K., Takamaru N., Ishimaru N., et al. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjogren's syndrome. J Rheumatol 33 (2006) 912-920
114. Motegi K., Azuma M., Tamatani T., Ashida Y., and Sato M. Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2′-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjogren's syndrome. Lab Invest 85 (2005) 342-353
115. Oki Y., Aoki E., and Issa J.P. Decitabine-bedside to bench. Crit Rev Oncol Hematol 61 (2007) 140-152
116. Ramos-Casals M., and Font J. Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 44 (2005) 1354-1367
117. Hayashi Y., Ishimaru N., Arakaki R., Tsukumo S., Fukui H., Kishihara K., et al. Effective treatment of a mouse model of Sjogren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum 50 (2004) 2903-2910
118. Arakaki R., Ishimaru N., Saito I., Kobayashi M., Yasui N., Sumida T., et al. Development of autoimmune exocrinopathy resembling Sjogren's syndrome in adoptively transferred mice with autoreactive CD4+ T cells. Arthritis Rheum 48 (2003) 3603-3609
119. Thompson C., Jacobsen H., Pomeranz Krummel D., Nagai K., and Cooke A. Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice. Autoimmunity 37 (2004) 549-554
120. Joraku A., Sullivan C.A., Yoo J.J., and Atala A. Tissue engineering of functional salivary gland tissue. Laryngoscope 115 (2005) 244-248
121. Tran S.D., Sugito T., Dipasquale G., Cotrim A.P., Bandyopadhyay B.C., Riddle K., et al. Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland. Tissue Eng (2006) Sep 1 [Epub ahead of print]
122. Selvam S., Thomas P.B., Trousdale M.D., Stevenson D., Schechter J.E., Mircheff A.K., et al. Tissue-engineered tear secretory system: functional lacrimal gland acinar cells cultured on matrix protein-coated substrata. J Biomed Mater Res B Appl Biomater (2006) [Epub ahead of print]
123. Geerling G., Sieg P., Bastian G.O., and Laqua H. Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca. Ophthalmology 105 2 (1998) 327-335
124. Yu G.Y., Zhu Z.H., Mao C., Cai Z.G., Zou L.H., Lu L., et al. Microvascular autologous submandibular gland transfer in severe cases of keratoconjunctivitis sicca. Oral Maxillofac Surg 33 (2004) 235-239
125. Soares E.J., and Franca V.P. Transplantation of labial salivary glands for severe dry eye treatment. Ar Qbras Oftalmol 68 (2005) 481-489
126. Ge X.Y., Yu G.Y., Cai Z.G., and Mao C. Establishment of submandibular gland allotransplantation model in miniature swine. Chin Med J (Engl) 119 (2006) 482-487
127. Tanaka Isomura E., Yoshitomi K., Hamaguchi M., Yamamoto Y.E., and Kogo M. Transplantation of vascularized submandibular gland in dogs. J Oral Maxillofac Surg 64 (2006) 1561-1565
128. Tsianos E.B., Chiras C.D., Drosos A.A., and Moutsopoulos H.M. Oesophageal dysfunction in patients with primary Sjogren's syndrome. Ann Rheum Dis 44 (1985) 610-613
129. Tabbara K.F., and Frayha R.A. Alternate-day steroid therapy for patients with primary Sjogren's syndrome. Ann Ophthalmol 15 (1983) 358-361
130. Zandbelt M.M., van den Hoogen F.H., de Wilde P.C., van den Berg P.J., Schneider H.G., and van de Putte L.B. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren's syndrome. Ann Rheum Dis 60 (2001) 511-513
131. Fox R.I., and Kang H.I. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 2 (1993) S9-S12
132. Sperber K., Quraishi H., Kalb T.H., Panja A., Stecher V., and Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 20 (1993) 803-808
133. Dawson L.J., Caulfield V.L., Stanbury J.B., Field A.E., Christmas S.E., and Smith P.M. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 44 (2005) 449-455
134. Lakhanpal S., Duffy J., Griffing W.L., Conn D.L., and Luthra H.S. Sjogren's syndrome: treatment with D-penicillamine and hydroxychloroquine. J Rheumatol 12 (1985) 1028-1029
135. Fox R.I., Chan E., Benton L., Fong S., Friedlaender M., and Howell F.V. Treatment of primary Sjogren's syndrome with hydroxychloroquine. Am J Med 85 (1988) 62-67
136. Kruize A.A., Hene R.J., Kallenberg C.G., van Bijsterveld O.P., van der Heide A., Kater L., et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 52 (1993) 360-364
137. Fox R.I., Dixon R., Guarrasi V., and Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 (1996) S31-S36
138. Tishler M., Yaron I., Shirazi I., and Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58 (1999) 253-256
139. Skopouli F.N., Jagiello P., Tsifetaki N., and Moutsopoulos H.M. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 14 (1996) 555-558
140. Price E.J., Rigby S.P., Clancy U., and Venables P.J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 25 (1998) 896-899
141. Yeoman C.M., and Franklin C.D. Assessment of sulphasalazine as a treatment modality in Sjogren's disease in NZB/NZW F1 hybrid mice. Clin Exp Rheumatol 14 (1996) 53-57
142. Merrin P., and Williams I.A. Meningitis associated with sulphasalazine in a patient with Sjogren's syndrome and polyarthritis. Ann Rheum Dis 50 (1991) 645-646
143. Crisp A.J., and Hoffbrand B.I. Sulphasalazine-induced systemic lupus erythematosus in a patient with Sjogren's syndrome. J R Soc Med 73 (1980) 60-61
144. Marinos G., Riley J., Painter D.M., and McCaughan G.W. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 14 (1992) 132-135
145. Steuer A., McCrea D.J., and Colaco C.B. Primary Sjogren's syndrome, ulcerative colitis and selective IgA deficiency. Postgrad Med J 72 (1996) 499-500
146. van Woerkom J., Kruize A.A., Geenen R., van Roon E.N., Goldschmeding R., Verstappen S.M., et al. Safety and efficacy of Leflunomide in primary Sjogren's syndrome-a phase II pilot study. Ann Rheum Dis (2007) Jan 12 [Epub ahead of print]
147. Choudhary A., Harding S.P., Bucknall R.C., and Pearce I.A. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther 22 (2006) 168-175
148. Ramos-Casals M., and Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14 suppl 1 (2005) s64-s72
149. Sutcliffe N., Inanc M., Speight P., and Isenberg D. Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 28 2 (1998) 80-87
150. Tzioufas A.G., Boumba D.S., Skopouli F.N., and Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 39 (1996) 767-772
151. Rogers S.J., Williams C.S., and Roman G.C. Myelopathy in Sjogren's syndrome: role of nonsteroidal immunosuppressants. Drugs 64 (2004) 123-132
152. de Seze J., Delalande S., Fauchais A.L., Hachulla E., Stojkovic T., Ferriby D., et al. Myelopathies secondary to Sjogren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol 33 (2006) 709-711
153. Goransson L.G., Herigstad A., Tjensvoll A.B., Harboe E., Mellgren S.I., and Omdal R. Peripheral neuropathy in primary sjogren syndrome: a population-based study. Arch Neurol 63 (2006) 1612-1615
154. Font J., Ramos-Casals M., de la Red G., Pou A., Casanova A., Garcia-Carrasco M., et al. Pure sensory neuropathy in primary Sjogren's syndrome. Long-term prospective follow-up and review of the literature. J Rheumatol 30 (2003) 1552-1557
155. Molina J.A., Benito-Leon J., Bermejo F., Jimenez-Jimenez F.J., and Olivan J. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 60 (1996) 699
156. Pascual J., Cid C., and Berciano J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjogren's syndrome. Neurology 51 (1998) 650-651
157. Kizawa M., Mori K., Iijima M., Koike H., Hattori N., and Sobue G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 77 (2006) 967-969
158. Takahashi Y., Takata T., Hoshino M., Sakurai M., and Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. Neurology 60 (2003) 503-505
159. Burns T.M., Quijano-Roy S., and Jones H.R. Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren's syndrome: comment. Neurology 61 (2003) 873
160. Wolfe G.I., Nations S.P., Burns D.K., Herbelin L.L., and Barohn R.J. Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. Neurology 61 (2003) 873
161. Cavill D., Waterman S.A., and Gordon T.P. Antiidiotypic antibodies neutralize auto-antibodies that inhibit cholinergic neurotransmission. Arthritis Rheum 48 (2003) 3597-3602
162. Bakchine S., Mas J.L., Rottembourg R., Wechsler B., Le Charpentier Y., and Derouesne C. Polyneuropathy disclosing primary Gougerot-Sjogren syndrome. Treatment by plasma exchange. Rev Neurol (Paris) 143 (1987) 839-840
163. Chen W.H., Yeh J.H., and Chiu H.C. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjogren's syndrome. Eur Neurol 45 (2001) 270-274
164. Asahina M., Kuwabara S., Asahina M., Nakajima M., and Hattori T. D-penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjogren's syndrome. Neurology 51 (1998) 1451-1453
165. Yamada S., Mori K., Matsuo K., Inukai A., Kawagashira Y., and Sobue G. Interferon alfa treatment for Sjogren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 76 (2005) 576-578
166. Caroyer J.M., Manto M.U., and Steinfeld S.D. Severe sensory neuronopathy responsive to infliximab in primary Sjogren's syndrome. Neurology 59 (2002) 1113-1114
167. Gorson K.C., Natarajan N., Ropper A.H., and Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35 (2007) 66-69
168. Goules A., Masouridi S., Tzioufas A.G., Ioannidis J.P., Skopouli F.N., and Moutsopoulos H.M. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore) 79 (2000) 241-249
169. Adam F.U., Torun D., Bolat F., Zumrutdal A., Sezer S., and Ozdemir F.N. Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjogren's syndrome. Clin Rheumatol 25 (2006) 75-79
170. Kau C.K., Hu J.C., Lu L.Y., Tseng J.C., Wang J.S., and Cheng H.H. Primary Sjogren's syndrome complicated with cryoglobulinemic glomerulonephritis, myocarditis, and multi-organ involvement. J Formos Med Assoc 103 (2004) 707-710
171. Tatsumi H., Tateno S., Hiki Y., Shigematsu H., and Kobayashi Y. Crescentic glomerulonephritis associated with membranous nephropathy in a case with primary Sjogren's syndrome. Nephrol Dial Transplant 13 (1998) 2624-2627
172. Iwanaga N., Kamachi M., Fujikawa K., Aramaki T., Izumi Y., Arima K., et al. Membraneous glomerulonephritis and non-Hodgkin's lymphoma in a patient with primary Sjogren's syndrome. Intern Med 46 (2007) 191-194
173. Ferri C., and Mascia M.T. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18 (2006) 54-63
174. Durez P., Tourne L., Feremans W., Mascart-Lemone F., Heenen M., and Appelboom T. Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren's syndrome. J Rheumatol 25 (1998) 1032-1033
175. Canhao H., Fonseca J.E., and Rosa A. Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren's syndrome. J Rheumatol 27 (2000) 1102-1103
176. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
177. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64 (2005) 913-920
178. Voulgarelis M., Giannouli S., Anagnostou D., and Tzioufas A.G. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 43 (2004) 1050-1053
179. Voulgarelis M., Giannouli S., Tzioufas A.G., and Moutsopoulos H.M. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 65 (2006) 1033-1037
180. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66 (2007) 351-357
181. Touma Z., Sayad J., and Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 35 (2006) 323-325
182. Schattner A., Friedman J., Klepfish A., and Berrebi A. Immune cytopenias as the presenting finding in primary Sjogren's syndrome. QJM 93 (2000) 825-829
183. Schattner A., Shtalrid M., and Berrebi A. Autoimmune hemolytic anemia preceding Sjogren's syndrome. J Rheumatol 10 (1983) 482-484
184. Coppo P., Sibilia J., Maloisel F., Schlageter M.H., Voyer A.L., Gouilleux-Gruart V., et al. Primary Sjogren's syndrome associated agranulocytosis: a benign disorder?. Ann Rheum Dis 62 (2003) 476-478
185. Friedman J., Klepfish A., Miller E.B., Ognenovski V., Ike R.W., and Schattner A. Agranulocytosis in Sjogren's syndrome: two case reports and analysis of 11 additional reported cases. Semin Arthritis Rheum 31 (2002) 338-345
186. Simon J.A., Lazo-Langner A., Duarte-Rojo A., Velazquez-Gonzalez A., Sanchez-Guerrero S.A., and Sanchez-Guerrero J. Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjogren's syndrome. J Clin Apher 17 (2002) 44-46
187. Yamanouchi J., Yokota E., Yamauchi Y., and Matsumoto I. [A case of Sjogren's syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy]. Ryumachi 38 (1998) 595-599
188. Campbell G.N., and Gallo J.H. Relapsing thrombotic thrombocytopenic purpura (TTP) in Sjogren's syndrome. Aust NZ J Med 28 (1998) 214
189. Schattner A., Friedman J., and Klepfish A. Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren's syndrome. Clin Rheumatol 21 (2002) 57-59
190. Abe H., Tsuboi N., Yukawa S., Tsuji S., Hayashi H., Yukawa N., et al. Thrombotic thrombocytopenic purpura complicating Sjogren's syndrome with crescentic glomerulonephritis and membranous nephritis. Mod Rheumatol 14 (2004) 174-178
191. Fox R.I., Kang H.I., Ando D., Abrams J., and Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 152 (1994) 5532-5539
192. Matsumura R., Umemiya K., Goto T., Nakazawa T., Ochiai K., Kagami M., et al. Intrferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 18 (2000) 311-318
193. Azuma M., Aota K., Tamatani T., Motegi K., Yamashita T., Harada K., et al. Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Arthritis Rheum 43 (2000) 1756-1767
194. Steinfeld S.D., Demols P., Salmon I., Kiss R., and Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 44 (2001) 2371-2375
195. Steinfeld S.D., Demols P., and Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 46 (2002) 3301-3303
196. Mariette X., Ravaud P., Steinfeld S., Baron G., Goetz J., Hachulla E., et al. Inefficacy of iniximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 50 (2004) 1270-1276
197. Sankar V., Brennan M.T., Kok M.R., Leakan R.A., Smith J.A., Manny J., et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50 (2004) 2240-2245
198. Zandbelt M.M., de Wilde P., van Damme P., Hoyng C.B., van de Putte L., and van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 31 (2004) 96-101
199. Moutsopoulos N.M., Angelov N., Sankar V., Leakan R.A., Pillemer S., and Wahl S.M. Immunological consequences of thalidomide treatment in Sjogren's syndrome. Ann Rheum Dis 65 (2006) 112-114
200. Pillemer S.R., Leakan R.A., Sankar V., Manny J., Baum B.J., Smith J., et al. Prominent adverse effects of thalidomide in primary Sjogren's syndrome. Arthritis Rheum 51 (2004) 505-506
201. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., and Jacobsson L.T. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65 (2006) 796-803
202. Theander E., Manthorpe R., and Jacobsson L.T. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 50 4 (2004) 1262-1269
203. Ansell S.M., and Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80 (2005) 1087-1097
204. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48 (2003) 1484-1492
205. Shih W.J., Ghesani N., Hongming Z., Alavi A., Schusper S., and Mozley D. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 27 (2002) 142-143
206. Somer B.G., Tsai D.E., Downs L., Weinstein B., and Schuster S.J. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49 (2003) 394-398
207. Harner K.C., Jackson L.W., and Drabick J.J. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford) 43 (2004) 1309-1310
208. Pijpe J., van Imhoff G.W., Vissink A., van der Wal J.E., Kluin P.M., Spijkervet F.K., et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 64 (2005) 958-960
209. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
210. Manz R.A., Arce S., Cassese G., Hauser A.E., Hiepe F., and Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14 (2002) 517-521
211. Ring T., Kallenbach M., Praetorius J., Nielsen S., and Melgaard B. Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin Rheumatol 25 (2006) 891-894
212. Lajaunias F., Ida A., Kikuchi S., Fossati-Jimack L., Martinez-Soria E., Moll T., et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum 48 (2003) 1612-1621
213. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9 (2003) 3982S-3990S
214. Strauss S.J., Morschhauser F., Rech J., Repp R., Solal-Celigny P., Zinzani P.L., et al. Phase II Multicenter Trial of Epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24 (2006) 3880-3886
215. Leonard J.P., Coleman M., Ketas J., Ashe M., Fiore J.M., Furman R.R., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 5044-5051
216. Dorner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R74
217. Steinfeld S.D., Tant L., Burmester G.R., Teoh N.K., Wegener W.A., Goldenberg D.M., et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren's syndrome: an open-label Phase I/II study. Arthritis Res Ther 8 (2006) R129
218. Carnahan J., Stein R., Qu Z., Hess K., Cesano A., Hansen H.J., et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44 (2007) 1331-1341
219. Voulgarelis M., Petroutsos G., Moutsopoulos H.M., and Skopouli F.N. 2-chloro-2′-deoxyadenosine in the treatment of Sjogren's syndrome-associated B cell lymphoproliferation. Arthritis Rheum 46 (2002) 2248-2249
220. Sullivan D.A., Belanger A., Cermak J.M., Berube R., Papas A.S., Sullivan R.M., et al. Are women with Sjogren's syndrome androgen-deficient?. J Rheumatol 30 11 (2003) 2413-2419
221. Valtysdottir S.T., Wide L., and Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol 28 (2001) 1259-1265
222. Brennan M.T., Sankar V., Leakan R.A., Grisius M.M., Collins M.T., Fox P.C., et al. Sex steroid hormones in primary Sjogren's syndrome. J Rheumatol 30 (2003) 1267-1271
223. Valtysdottir S.T., Wide L., and Hallgren R. Mental wellbeing and quality of sexual life in women with primary Sjogren's syndrome are related to circulating dehydro-epiandrosterone sulphate. Ann Rheum Dis 62 (2003) 875-879
224. Pillemer S.R., Brennan M.T., Sankar V., Leakan R.A., Smith J.A., Grisius M., et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren's syndrome. Arthritis Rheum 51 (2004) 601-604
225. van Vollenhoven R. Dehydroepiandrosterone versus placebo for Sjogren's syndrome: comment on the article by Pillemer et al. Arthritis Rheum 53 (2005) 626
226. Phan T.G., Gordon T.P., Tattersall M.H., and Loblay R.H. Octreotide therapy for the Sjogren syndrome. Ann Intern Med 137 (2002) 777-778
227. Lichtenauer-Kaligis E.G., van Hagen P.M., Lamberts S.W., and Hofland L.J. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 143 (2000) S21-S25
228. Ferone D., van Hagen P.M., Semino C., Dalm V.A., Barreca A., Colao A., et al. Somatostatin receptor distribution and function in immune system. Dig Liver Dis 36 (2004) S68-S77
229. van Hagen P.M. Somatostatin receptor expression in clinical immunology. Metabolism 45 (1996) S86-S87
230. Steinfeld S.D., Demols P., Van Vooren J.P., Cogan E., and Appelboom T. Zidovudine in primary Sjogren's syndrome. Rheumatology (Oxford) 38 (1999) 814-817
231. Pot C., Chizzolini C., Vokatch N., Tiercy J.M., Ribi C., Landis T., et al. Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjogren-associated myelopathy. Arch Neurol 63 (2006) 1318-1320
232. Andres E., Blickle F., Sordet C., Cohen-Solal J., Sibilia J., and Sapin R. Primary Sjogren's syndrome and vitamin B12 deficiency: preliminary results in 80 patients. Am J Med 119 (2006) e9-e10
233. Szodoray P., and Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 62 (2005) 421-428
234. Hansen A., Lipsky P.E., and Dorner T. Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17 (2005) 558-565
235. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109 (2002) 59-68
236. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 (2003) 168-171
237. Szodoray P., Jellestad S., Alex P., Zhou T., Wilson P.C., Centola M., et al. Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren's syndrome with a special emphasis on BAFF. J Clin Immunol 24 (2004) 600-611
238. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., and Mariette X. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis (2006) Oct 13 [Epub ahead of print]
239. Bolstad A.I., Eiken H.G., Rosenlund B., Alarcon-Riquelme M.E., and Jonsson R. Increased salivary gland tissue expression of Fas. Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 48 (2003) 174-185
240. Downie-Doyle S., Bayat N., Rischmueller M., and Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. Arthritis Rheum 54 (2006) 2434-2440
241. Hadj Kacem H., Kaddour N., Adyel F.Z., Bahloul Z., and Ayadi H. HLA-DQB1 CAR1/CAR2. TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjogren's syndrome. Rheumatology (Oxford) 40 (2001) 1370-1374
242. Nicolls M.R., and Gill R.G. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 6 (2006) 27-36
243. http://clinicaltrials.gov/ct/show/NCT00344448 accessed February 27, 2007.
244. Halse A., Tengner P., Wahren-Herlenius M., Haga H., and Jonsson R. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren's syndrome. Scand J Immunol 49 (1999) 533-538
245. Bertorello R., Cordone M.P., Contini P., Rossi P., Indiveri F., Puppo F., et al. Increased levels of interleukin-10 in saliva of Sjogren's syndrome patients. Correlation with disease activity. Clin Exp Med 4 (2004) 148-151
246. Zhu Z., Stevenson D., Schechter J.E., Mircheff A.K., Ritter T., Labree L., et al. Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis. Invest Ophthalmol Vis Sci 45 (2004) 1375-1381
247. Bombardieri M., Barone F., Pittoni V., Alessandri C., Conigliaro P., Blades M.C., et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 6 (2004) R447-R456
248. Nordmark G., Alm G.V., and Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2 (2006) 262-269
249. Hasegawa H., Inoue A., Kohno M., Muraoka M., Miyazaki T., Terada M., et al. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates thprogression of autoimmune sialadenitis in MRL/lpr mice. Arthritis Rheum 54 (2006) 1174-1183
250. Kurien B.T., Asfa S., Li C., Dorri Y., Jonsson R., and Scofield R.H. Induction of oral tolerance in experimental Sjogren's syndrome autoimmunity. Scand J Immunol 61 (2005) 418-425
251. Scofield R.H., Asfa S., Obeso D., Jonsson R., and Kurien B.T. Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjogren's syndrome. J Immunol 175 (2005) 8409-8414